cell cycle assay kit (Elabscience Biotechnology)
Elabscience Biotechnology is a verified supplier 
Elabscience Biotechnology manufactures this product 
96
Structured Review
Elabscience Biotechnology
cell cycle assay kit
Cell Cycle Assay Kit, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 329 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cell+cycle+kit/Cell+Cycle+Assay+Kit/pm41661446-57-7-11
Average 96 stars, based on 329 article reviews
Cell Cycle Assay Kit, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 329 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cell+cycle+kit/Cell+Cycle+Assay+Kit/pm41661446-57-7-11
Average 96 stars, based on 329 article reviews
cell cycle assay kit - by Bioz Stars,
2026-11
96/100 stars
Images
Related Articles
Cell Cycle Assay:Article Title: Antiproliferative, Cytotoxic, and Antimigratory Effects of Licochalcone A in Ishikawa Endometrial Cancer Cells Article Snippet: Following treatment, cells were detached using trypsin/EDTA, collected by centrifugation, and washed three times with phosphatebuffered saline (PBS; Cat. No. P4417; Sigma-Aldrich, St. Louis, MO, USA). .. Cell cycle distribution was analyzed using a Article Title: Liquiritin Enhances Chemosensitivity to Doxorubicin in Breast Cancer by Promoting Ubiquitination-Mediated Degradation of MCL1. Article Snippet: Breast cancer (BC) represents a life‐threatening malignant disease that profoundly endangers women's health, with chemoresistance restricting treatment efficacy.. Liquiritin (LIQ) has shown great potential in cancer therapy, yet its effect on the chemosensitivity of BC cells remains unclear.. BC cells were treated with different concentration gradients of Doxorubicin (DOX) and LIQ. Article Title: Combination Therapeutic Effect of Psoralen and Paclitaxel-Loaded Superparamagnetic Iron Oxide Nanoparticles for the Treatment of Triple-Negative Breast Cancer Article Snippet: .. Article Title: Metformin Inhibits the Growth of Hypopharyngeal Squamous Cell Carcinoma of Fadu Cell and Down-Regulates LncAROD to Improve Prognosis. Article Snippet: Background: Hypopharyngeal Squamous Cell Carcinoma (HSCC) is associated with a poor prognosis due to challenges in early detection, early metastasis, and limited treatment options.. Objective: This study aims to investigate the effect of metformin on HSCC and identify potential prognostic factors associated with this carcinoma.. Methods: The effects of metformin in HSCC cells were tested by functional assays in vitro. Article Title: Combination Therapeutic Effect of Psoralen and Paclitaxel-Loaded Superparamagnetic Iron Oxide Nanoparticles for the Treatment of Triple-Negative Breast Cancer Article Snippet: .. Article Title: A biomimetic nanoplatform for targeted co-delivery of ABT-199 and ATRA potentiates acute myeloid leukemia therapy via DNA damage response suppression. Article Snippet: Despite its clinical utility, the therapeutic potential of Venetoclax (ABT-199) in acute myeloid leukemia (AML) remains limited by the heterogeneous nature of the disease, which often leads to reduced efficacy of monotherapy.. Herein, we demonstrate that ABT-199-induced apoptosis can be potentiated by all-trans retinoic acid (ATRA) to suppress the DNA damage response.. To address the lack of targeted drug delivery against AML and facilitate enhanced therapeutic efficacy, we engineered a biomimetic micelle, HPAA, by co-assembling an amphiphilic mPEG-ATRA conjugate with ABT-199 into micelles, followed by cloaking with P-selectin-rich membranes from activated human umbilical vein endothelial cells to target CD44 overexpressed on AML cells. Staining:Article Title: Antiproliferative, Cytotoxic, and Antimigratory Effects of Licochalcone A in Ishikawa Endometrial Cancer Cells Article Snippet: Following treatment, cells were detached using trypsin/EDTA, collected by centrifugation, and washed three times with phosphatebuffered saline (PBS; Cat. No. P4417; Sigma-Aldrich, St. Louis, MO, USA). .. Cell cycle distribution was analyzed using a Article Title: KDM3B Predicts Expression Signature, Prognosis Value, and Immune Characteristics of Cancers: A Pan‐Cancer Analysis Article Snippet: .. Subsequently, the cells were incubated with RNase A at 37°C for 30 min, stained with 200 μ L of 50‐ μ g/mL Incubation:Article Title: KDM3B Predicts Expression Signature, Prognosis Value, and Immune Characteristics of Cancers: A Pan‐Cancer Analysis Article Snippet: .. Subsequently, the cells were incubated with RNase A at 37°C for 30 min, stained with 200 μ L of 50‐ μ g/mL Flow Cytometry:Article Title: KDM3B Predicts Expression Signature, Prognosis Value, and Immune Characteristics of Cancers: A Pan‐Cancer Analysis Article Snippet: .. Subsequently, the cells were incubated with RNase A at 37°C for 30 min, stained with 200 μ L of 50‐ μ g/mL other:Article Title: Diverse roles of SERPINE1 in regulating cellular proliferation and invasion Article Snippet: Weighted correlation network analysis (WGCNA) was performed using the OmicShare platform ( https://www.omicshare.com/tools ) to identify co-expression modules. Red Blood Cell Lysis:Article Title: A biomimetic nanoplatform for targeted co-delivery of ABT-199 and ATRA potentiates acute myeloid leukemia therapy via DNA damage response suppression. Article Snippet: Despite its clinical utility, the therapeutic potential of Venetoclax (ABT-199) in acute myeloid leukemia (AML) remains limited by the heterogeneous nature of the disease, which often leads to reduced efficacy of monotherapy.. Herein, we demonstrate that ABT-199-induced apoptosis can be potentiated by all-trans retinoic acid (ATRA) to suppress the DNA damage response.. To address the lack of targeted drug delivery against AML and facilitate enhanced therapeutic efficacy, we engineered a biomimetic micelle, HPAA, by co-assembling an amphiphilic mPEG-ATRA conjugate with ABT-199 into micelles, followed by cloaking with P-selectin-rich membranes from activated human umbilical vein endothelial cells to target CD44 overexpressed on AML cells. |